Welcome to our dedicated page for Bioadaptives SEC filings (Ticker: BDPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAdaptives, Inc. filings document the company’s public-reporting obligations as an OTC operating company. The Form 12b-25 notice relates to a delayed Form 10-K for the year ended December 31, 2025 and identifies the annual report process under Rule 12b-25.
For this issuer, formal disclosures center on registrant identity, reporting deadlines, annual-report timing and related compliance statements rather than product-launch detail. The filing record provides regulatory context for BioAdaptives’ nutraceutical and wellness business as it reports as a public company.
Bioadaptives, Inc. disclosed that a director filed a Form 4 reporting equity compensation in the form of preferred stock. On 12/01/2025, the director received 2,025 shares of Series D Convertible Preferred Stock as compensation for board services under a Board of Directors Agreement dated February 3, 2025. Each preferred share is convertible into 100 shares of common stock, for a total of 202,500 underlying common shares, but conversions are subject to a 4.9% beneficial ownership limitation.
The preferred shares generally cannot be converted until six months after issuance, except that conversion occurs immediately in a liquidation. Each preferred share carries 100 votes on stockholder matters and the conversion right does not expire. After this transaction, the reporting person beneficially owned 54,931 derivative securities, held directly.
BioAdaptives, Inc. (BDPT) reported Q3 2025 results, showing a wider net loss and continued liquidity pressure. Net loss was $379,502 for the quarter, compared with $37,649 a year ago, as operating expenses and derivative fair value changes weighed on results. Revenue reached $4,632 in Q3 as limited PawPa Regen sales began.
For the nine months, net loss totaled $734,552 on revenue of $7,851. Cash was $59,273 at September 30, 2025, with current assets of $108,860 versus current liabilities of $1,589,570, resulting in a working capital deficiency of $1,480,710. The company reported a stockholders’ deficit of $1,465,210, including derivative liabilities of $967,406 and convertible notes of $359,300.
Management disclosed substantial doubt about the company’s ability to continue as a going concern and noted material weaknesses in internal controls. Financing activities included $300,000 of cash proceeds from Series D preferred stock and debt-to-equity conversions. Common shares outstanding were 12,008,659 as of October 17, 2025.
BioAdaptives (BDPT) director filed a Form 4 reporting the acquisition of 1,382 shares of Series D Convertible Preferred Stock on 11/01/2025, issued as compensation for board services. The filing lists a $0 price for the derivative award.
Each Series D share is convertible into common stock at a 100:1 ratio, corresponding to 138,200 underlying common shares, subject to a 4.9% beneficial ownership limitation. The Series D shares become convertible six months after issuance (stated as 05/01/2026), with conversion occurring immediately in a liquidation scenario. Each Series D share carries 100 votes on matters of the issuer, and the right to convert does not expire.
Mark P. Frissora, a director of BioAdaptives, Inc. (BDPT), received compensation in the form of Series D Convertible Preferred Stock on 10/01/2025. He was issued 1,517 shares of Series D Convertible Preferred Stock as board-service compensation under a Board of Directors Agreement dated 02/03/2025. Each preferred share converts into 100 shares of common stock, so the issuance represents economic exposure to 151,700 common shares, subject to a 10% beneficial ownership cap. Conversions are restricted for six months from issuance (except on liquidation), and each Series D preferred share carries 100 votes at stockholder meetings. The reporting indicates direct ownership following the transaction and no cash price was paid for the preferred shares.